This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKPositive Net Change GILDNegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
by Zacks Equity Research
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
ALKSNegative Net Change CRMDPositive Net Change AVDLPositive Net Change CSTLPositive Net Change
biotechs
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
by Zacks Equity Research
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
BIAFPositive Net Change
biotechnology biotechs earnings medical
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
by Zacks Equity Research
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
ALKSNegative Net Change INSMPositive Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
by Zacks Equity Research
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
NVOPositive Net Change VNDAPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
by Zacks Equity Research
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
ALKSNegative Net Change JAZZNegative Net Change CRMDPositive Net Change ZYMENegative Net Change
biotechs medical
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
NVOPositive Net Change ADMAPositive Net Change ARQTNegative Net Change VTYXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
GSKNegative Net Change ADMAPositive Net Change ALECNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
by Sundeep Ganoria
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
BIIBPositive Net Change JNJNegative Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
by Zacks Equity Research
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
RHHBYNegative Net Change ALKSNegative Net Change SRPTPositive Net Change CRMDPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
by Zacks Equity Research
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
BMYNegative Net Change JNJNegative Net Change CYTKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
by Kanishka Das
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
TEVAPositive Net Change ANIPPositive Net Change AMRXNo Net Change VTRSPositive Net Change
biotechs medical
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
by Zacks Equity Research
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
GSKNegative Net Change ALKSNegative Net Change GILDNegative Net Change FOLDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
ANIPPositive Net Change ADMAPositive Net Change KODPositive Net Change ARQTNegative Net Change
biotechnology biotechs earnings medical
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
BMYNegative Net Change ALKSNegative Net Change FOLDNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
NVSNegative Net Change ANIPPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Undervalued Stocks That Are Poised for Growth in November
by Kinjel Shah
Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.
GLDDPositive Net Change ENSPositive Net Change STNEPositive Net Change KROSNegative Net Change MLKNNegative Net Change
batteries biotechs computers construction
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
by Sundeep Ganoria
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
JNJNegative Net Change LLYNegative Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
by Ahan Chakraborty
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
ALKSNegative Net Change FOLDNegative Net Change CRMDPositive Net Change IMVTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals